Giil Lasse Melvaer, Solvang Stein-Erik Hafstad, Giil Malin Melvaer, Hellton Kristoffer H, Skogseth Ragnhild Eide, Vik-Mo Audun Osland, Hortobágyi Tibor, Aarsland Dag, Nordrehaug Jan Erik
Department of Internal Medicine, Haraldsplass Deaconess Hospital, Bergen, Norway.
Institute of Clinical Sciences, University of Bergen, Norway.
J Alzheimers Dis. 2019;68(1):239-253. doi: 10.3233/JAD-181131.
Epidemiological studies link serum potassium (K+) to cognitive performance, but whether cognitive prognosis in dementia is related to K+ levels is unknown.
To determine if K+ levels predict cognitive prognosis in dementia and if this varies according to diagnosis or neuropathological findings.
This longitudinal cohort study recruited 183 patients with mild Alzheimer's disease or Lewy body dementia (LBD). Serum K+ and eGFR were measured at baseline and medications which could affect K+ registered. The Mini-Mental State Examination (MMSE) was measured annually over 5 years, and mortality registered. Association between K+ and √(30 -MMSE) was estimated overall, and according to diagnosis (joint model). Associations between MMSE-decline and K+ were assessed in two subgroups with neuropathological examination (linear regression) or repeated measurements of K+ over 3 years (mixed model).
Serum K+ at baseline was associated with more errors on MMSE over time (Estimate 0.18, p = 0.003), more so in LBD (p = 0.048). The overall association and LBD interaction were only significant in the 122 patients not using K+ relevant medication. Repeated K+ measures indicated that the association with MMSE errors over time was due to a between-person effect (p < 0.05, n = 57). The association between the annual MMSE decline was stronger in patients with autopsy confirmed LBD and more α-synuclein pathology (all: p < 0.05, n = 41).
Higher serum K+ predicts poorer cognitive prognosis in demented patients not using medications which affect K+, likely a between-person effect seen mainly in LBD.
流行病学研究将血清钾(K+)与认知功能联系起来,但痴呆症的认知预后是否与K+水平相关尚不清楚。
确定K+水平是否能预测痴呆症的认知预后,以及这是否因诊断或神经病理学发现而异。
这项纵向队列研究招募了183例轻度阿尔茨海默病或路易体痴呆(LBD)患者。在基线时测量血清K+和估算肾小球滤过率(eGFR),并记录可能影响K+的药物。在5年时间里每年测量简易精神状态检查表(MMSE),并记录死亡率。总体上以及根据诊断(联合模型)估计K+与√(30 - MMSE)之间的关联。在两个亚组中评估MMSE下降与K+之间的关联,一个亚组进行神经病理学检查(线性回归),另一个亚组在3年时间里重复测量K+(混合模型)。
基线时的血清K+与MMSE随时间出现更多错误相关(估计值0.18,p = 0.003),在LBD中更明显(p = 0.048)。总体关联和LBD相互作用仅在122例未使用与K+相关药物的患者中显著。重复的K+测量表明,随时间与MMSE错误的关联是由于个体间效应(p < 0.05,n = 57)。在尸检确诊为LBD且α-突触核蛋白病理改变更多的患者中,年度MMSE下降之间的关联更强(所有p < 0.05,n = 41)。
较高的血清K+预示着未使用影响K+药物的痴呆患者认知预后较差,这可能主要是LBD中出现的个体间效应。